Core Insights - TG Therapeutics, Inc. will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, with a fireside chat scheduled for June 4, 2025, at 12:50 PM ET [1] Company Overview - TG Therapeutics is a fully integrated, commercial stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases [3] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating adult patients with relapsing forms of multiple sclerosis (RMS) [3] - BRIUMVI has also been approved by the European Commission and the Medicines and Healthcare Products Regulatory Agency for treating adult patients with RMS who have active disease [3]

Core Insights - TG Therapeutics presented data on BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting [1][2] - The company is optimistic about the ongoing data presentations throughout the year [2] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI approved for RMS treatment in the U.S., Europe, and the UK [23] - The company has a pipeline of investigational medicines in addition to BRIUMVI [23] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed to deplete B-cells efficiently at low doses through glycoengineering [4] - It is indicated for adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [5] Clinical Trials - The ULTIMATE I & II trials involved 1,094 RMS patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3] - The trials required patients to have experienced at least one relapse in the previous year or two relapses in the previous two years, with specific EDSS score criteria [3] Safety and Efficacy Data - Presentations at the CMSC included findings on the safety and tolerability of BRIUMVI, with a focus on infusion reactions and immunoglobulin levels [2][6] - The incidence of infusion reactions in BRIUMVI-treated patients was reported at 48%, with serious reactions occurring in 0.6% of patients [6][8] - The overall infection rate in BRIUMVI-treated patients was 56%, with serious infections at 5% [8] Market Context - Relapsing multiple sclerosis affects nearly 1 million people in the U.S., with 85% initially diagnosed with relapsing-remitting forms [22] - The global prevalence of MS is over 2.3 million [22]

Company Overview - TG Therapeutics (NASDAQ: TGTX) is a commercial stage biotech company focused on Briumvi, a treatment for multiple sclerosis [1] Investment Strategy - The investment approach involves careful analysis of earnings reports to identify potential growth opportunities, with past successes including companies like OPRX, OTRK, FUBO, and PLUG [1]

Core Insights - TG Therapeutics, Inc. announced the presentation schedule for BRIUMVI (ublituximab-xiiy) data at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, focusing on its efficacy in patients with relapsing forms of multiple sclerosis (RMS) [1][2] Company Overview - TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases, with BRIUMVI approved for treating adult patients with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease [24][25] Product Information - BRIUMVI is a monoclonal antibody targeting CD20-expressing B-cells, designed through glycoengineering to enhance B-cell depletion at lower doses [4] - The drug is indicated for adults with RMS, which includes various forms of the disease [6] Clinical Trials - The ULTIMATE I & II Phase 3 trials involved 1,094 patients across 10 countries, comparing BRIUMVI to teriflunomide over 96 weeks [3] - Patients in these trials had experienced at least one relapse in the previous year or had specific MRI findings [3] Presentation Details - Presentations at the CMSC meeting include topics on the safety and tolerability of BRIUMVI, with specific focus on infusion reactions and real-world observational data [2][5]

[Special Cautionary Notice Regarding Forward-Looking Statements](index=3&type=section&id=SPECIAL%20CAUTIONARY%20NOTICE%20REGARDING%20FORWARD-LOOKING%20STATEMENTS) This section cautions that the report contains forward-looking statements subject to safe harbor provisions, where actual results may differ materially due to various risks [Special Cautionary Notice Regarding Forward-Looking Statements](index=3&type=section&id=SPECIAL%20CAUTIONARY%20NOTICE%20REGARDING%20FORWARD-LOOKING%20STATEMENTS) This section details the report's forward-looking statements, which are subject to safe harbor provisions and involve known and unknown risks that could cause actual results to differ materially - The report's forward-looking statements are protected under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995[9](index=9&type=chunk) - Key areas covered by forward-looking statements include regulatory approvals for products like BRIUMVI and azer-cel, commercialization success, manufacturing reliability, financial projections, capital requirements, and competitive developments[10](index=10&type=chunk) [Summary Risk Factors](index=4&type=section&id=SUMMARY%20RISK%20FACTORS) This section provides a high-level overview of principal risks associated with investing in the company, categorized by commercialization, financial, and operational areas [Summary Risk Factors](index=4&type=section&id=SUMMARY%20RISK%20FACTORS) This section summarizes the principal risks of investing in the company, covering commercialization, financial position, drug development, regulatory, third-party dependence, and intellectual property challenges - Commercialization risks include achieving market acceptance for BRIUMVI, facing substantial competition, and potential product liability lawsuits[12](index=12&type=chunk)[15](index=15&type=chunk) - Financial risks highlighted are a history of significant operating losses, potential future need for additional capital, and the adverse effects of indebtedness[13](index=13&type=chunk)[15](index=15&type=chunk) - Drug development and regulatory risks involve the uncertainty of obtaining and maintaining approvals, the potential for undesirable side effects, and navigating extensive and costly regulations[13](index=13&type=chunk)[15](index=15&type=chunk) - The company is heavily reliant on third parties for manufacturing, clinical trials, and in-licensed products, which poses significant operational risks[16](index=16&type=chunk)[20](index=20&type=chunk) - Intellectual property risks center on the ability to obtain, protect, and enforce patents and trade secrets, which is critical for commercial success[17](index=17&type=chunk)[20](index=20&type=chunk) [PART I: Financial Information](index=6&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) This part presents the company's unaudited condensed consolidated financial statements and management's discussion and analysis for the quarter ended March 31, 2025 [Item 1. Financial Statements](index=6&type=section&id=Item%201%20Financial%20Statements%3A) This section presents the unaudited condensed consolidated financial statements for Q1 2025, showing a net income of **$5.1 million** driven by strong product revenue growth [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets increased to **$656.7 million**, driven by higher accounts receivable and inventories, while total liabilities also rose to **$419.4 million** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $132,139 | $179,894 | | Accounts receivable, net | $190,121 | $129,185 | | Inventories | $157,759 | $110,458 | | **Total Assets** | **$656,689** | **$577,690** | | **Liabilities & Equity** | | | | Accounts payable and accrued expenses | $133,932 | $58,296 | | Loan payable – non-current | $244,733 | $244,429 | | **Total Liabilities** | **$419,400** | **$355,326** | | **Total Stockholders' Equity** | **$237,289** | **$222,364** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20%28unaudited%29) For Q1 2025, the company achieved profitability with a net income of **$5.1 million**, a significant improvement from a **$10.7 million** net loss in Q1 2024, driven by a **137%** increase in net product revenue Statement of Operations Summary (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Product revenue, net | $119,655 | $50,488 | | Total revenue | $120,856 | $63,474 | | Total costs and expenses | $112,234 | $72,744 | | Operating income (loss) | $8,622 | ($9,270) | | Net income (loss) | $5,060 | ($10,707) | | Diluted net income (loss) per share | $0.03 | ($0.07) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows%20%28unaudited%29) Net cash used in operating activities for Q1 2025 increased to **$28.7 million**, primarily due to higher accounts receivable and inventory, resulting in a **$47.8 million** net decrease in cash Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($28,715) | ($8,207) | | Net cash used in investing activities | ($12,934) | ($9,255) | | Net cash (used in) provided by financing activities | ($6,102) | $10 | | **Net Decrease in Cash** | **($47,751)** | **($17,452)** | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements%20%28unaudited%29) The notes provide detailed explanations of the company's accounting policies and financial statement line items, including revenue recognition, inventory valuation, debt facilities, and significant license agreements - The company is a commercial-stage biopharmaceutical firm focused on B-cell diseases, with BRIUMVI approved in the US, EU, and UK for relapsing forms of multiple sclerosis (RMS)[32](index=32&type=chunk) - As of March 31, 2025, the company had **$276.2 million** in cash, cash equivalents, and short-term investments, which is anticipated to be sufficient for more than twelve months of operations[35](index=35&type=chunk) - In August 2024, the company entered into a new **$250 million** term loan facility with Blue Owl Capital, refinancing its previous debt[100](index=100&type=chunk) - The company has a commercialization agreement with Neuraxpharm for BRIUMVI outside the US, receiving **$140 million** upfront and a **$12.5 million** milestone payment, with potential for up to **$492.5 million** in additional milestones[114](index=114&type=chunk) - In January 2024, the company licensed azer-cel, an allogeneic CAR T therapy, from Precision BioSciences for autoimmune diseases, with an upfront payment of **$7.5 million** and potential for **$288 million** in future milestones[118](index=118&type=chunk)[119](index=119&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=28&type=section&id=Item%202%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on the company's financial condition and results of operations, highlighting BRIUMVI's strong commercial performance and liquidity position Q1 2025 vs Q1 2024 Results of Operations (in thousands) | Line Item | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Product revenue, net | $119,655 | $50,488 | +137.0% | | Total Revenue | $120,856 | $63,474 | +90.4% | | Cost of revenue | $15,541 | $5,441 | +185.6% | | Total R&D | $46,362 | $32,722 | +41.7% | | Total SG&A | $50,331 | $34,581 | +45.5% | | Net income (loss) | $5,060 | ($10,707) | N/A | - The significant increase in net product revenue was due to greater market penetration of BRIUMVI in the United States[139](index=139&type=chunk) - Research and development expenses increased primarily due to manufacturing costs associated with the ublituximab subcutaneous development program[143](index=143&type=chunk) - Selling, general and administrative expenses rose due to increased costs associated with the commercialization of BRIUMVI[145](index=145&type=chunk) - The company anticipates its cash, cash equivalents, and investment securities, combined with projected BRIUMVI revenues, will provide sufficient liquidity for more than 12 months[149](index=149&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=33&type=section&id=Item%203%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company reports no material changes in its market risk exposure since the prior annual report - There have been no material changes in the company's market risk exposure since the last annual report[155](index=155&type=chunk) [Item 4. Controls and Procedures](index=33&type=section&id=Item%204%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the quarter[156](index=156&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[157](index=157&type=chunk) [PART II: Other Information](index=34&type=section&id=PART%20II%20OTHER%20INFORMATION) This part covers other important information including legal proceedings, detailed risk factors, equity sales, and exhibits [Item 1. Legal Proceedings](index=34&type=section&id=Item%201%20Legal%20Proceedings) The company reports no involvement in any material pending legal proceedings - The company is not currently involved in any material legal proceedings[158](index=158&type=chunk) [Item 1A. Risk Factors](index=34&type=section&id=Item%201A%20Risk%20Factors) This section extensively discusses risks and uncertainties that could adversely affect the company's business, financial condition, and operating results [Risks Related to Commercialization](index=35&type=section&id=Risks%20Related%20to%20Commercialization) This subsection details risks associated with commercializing BRIUMVI and future products, including market acceptance, competition, pricing, and product liability - Failure to achieve broad market acceptance for BRIUMVI among physicians, patients, and payors could significantly limit revenue[161](index=161&type=chunk) - The company faces substantial competition from large pharmaceutical companies with greater resources and established market presence in the neurological and immunological fields[173](index=173&type=chunk) - The business is vulnerable to unfavorable pricing regulations, cost-containment efforts by payors, and challenges in securing adequate reimbursement, which could harm profitability[177](index=177&type=chunk)[179](index=179&type=chunk) [Risks Related to Financial Position and Capital Needs](index=40&type=section&id=Risks%20Related%20to%20Our%20Financial%20Position%20and%20Need%20for%20Additional%20Capital) This subsection outlines financial risks, including a history of operating losses, potential future capital needs, and the significant indebtedness from the **$250 million** term loan - Despite recent net income, the company has a history of significant operating losses and may incur losses in the future, as profitability depends on sustained revenue from BRIUMVI[190](index=190&type=chunk)[191](index=191&type=chunk) - The company may need to raise additional capital, and an inability to do so on acceptable terms could require delaying or eliminating drug development or commercialization efforts[195](index=195&type=chunk) - The **$250 million** term loan from Blue Owl Capital imposes significant debt service obligations and restrictive covenants that could adversely affect financial condition and operational flexibility[202](index=202&type=chunk)[206](index=206&type=chunk) [Risks Related to Drug Development and Regulatory Approval](index=44&type=section&id=Risks%20Related%20to%20Drug%20Development%20and%20Regulatory%20Approval) This subsection covers inherent uncertainties of drug development, including trial success predictability, lengthy processes, potential side effects, and complex regulatory hurdles - Early-stage clinical trial results are not necessarily predictive of future success, and product candidates face a high rate of failure in later-stage trials[211](index=211&type=chunk) - Clinical development is a long, expensive, and uncertain process; delays in trial completion or negative results could prevent or delay commercialization[217](index=217&type=chunk) - Undesirable side effects from product candidates could delay or prevent regulatory approval, or if discovered post-approval, could lead to market withdrawal or a more restrictive label[226](index=226&type=chunk) [Risks Related to Dependence on Third Parties](index=62&type=section&id=Risks%20Related%20to%20Our%20Dependence%20on%20Third%20Parties) This subsection highlights the company's significant reliance on third parties for clinical trials, manufacturing, and intellectual property, posing operational and development risks - The company relies on third-party CROs to conduct clinical trials, and any failure by them to perform adequately could delay or terminate trials and jeopardize regulatory approval[286](index=286&type=chunk) - The company contracts with third parties like Samsung Biologics for the sole-source manufacture of BRIUMVI, increasing the risk of supply disruptions that could impair commercialization[290](index=290&type=chunk) - As products are in-licensed, any dispute with or non-performance by licensors (e.g., LFB Group for BRIUMVI) could adversely affect the ability to develop and commercialize the products[300](index=300&type=chunk) [Risks Related to Intellectual Property](index=68&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) This subsection discusses the critical importance and risks of intellectual property, including obtaining and defending patents, potential infringement, and protecting trade secrets - Commercial success is highly dependent on obtaining and maintaining robust patent protection for products like BRIUMVI; if patent scope is insufficient, competitors could develop similar drugs[314](index=314&type=chunk)[315](index=315&type=chunk) - The company may be involved in expensive and time-consuming lawsuits to enforce its patents or defend against claims that it infringes on third-party intellectual property[336](index=336&type=chunk)[342](index=342&type=chunk) - Failure to protect the confidentiality of trade secrets could harm the company's competitive position, as this is a primary form of intellectual property for its proprietary compound library[349](index=349&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=84&type=section&id=Item%202%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the company's share repurchase activity, including the **$100 million** authorized program and **$6.1 million** in repurchases during Q1 2025 - The company has a share repurchase program authorized for up to **$100 million** of its common stock, which was approved in August 2024[390](index=390&type=chunk) Q1 2025 Share Repurchases | Period | Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | January 2025 | 99,835 | $30.13 | | February 2025 | 94,860 | $31.28 | | March 2025 | 5,000 | $29.28 | | **Total Q1 2025** | **199,695** | **$30.23** | - As of March 31, 2025, approximately **$85.1 million** remained available for future repurchases under the program[387](index=387&type=chunk) [Item 3. Defaults Upon Senior Securities](index=85&type=section&id=Item%203%20Defaults%20of%20Senior%20Securities) The company reports no defaults upon senior securities during the period - None [Item 5. Other Information](index=85&type=section&id=Item%205%20Other%20Information) The company states that no directors or executive officers adopted or terminated Rule 10b5-1 trading plans during Q1 2025 - No directors or executive officers adopted or terminated Rule 10b5-1 trading plans during the quarter[393](index=393&type=chunk) [Item 6. Exhibits](index=85&type=section&id=Item%206%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and iXBRL data files - The exhibits include certifications from the CEO and CFO as required by the Sarbanes-Oxley Act of 2002[396](index=396&type=chunk)

Financial Performance - TG Therapeutics reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents [1] - The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million [1] Product Performance - Briumvi's U.S. net sales reached $119.7 million, demonstrating growing confidence in the treatment and increasing adoption by healthcare providers [2][3] - The company presented five-year data from the ULTIMATE I & II Phase 3 trials, showing that 92% of patients were free from disability progression after five years, with an annualized relapse rate of 0.02 during year 5 [4] - No new safety signals emerged over five years of continuous treatment, with no observed cases of progressive multifocal leukoencephalopathy (PML) [4] Future Guidance - TG Therapeutics raised Briumvi's U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance [5] - The total global revenue target was raised to $575 million from prior guidance of $540 million [5] - Briumvi's U.S. net product revenue is expected to be $135 million in the second quarter of 2025 [5] Stock Performance - TGTX stock was down 13.2% at $37.68 on Monday [6]

Core Insights - TG Therapeutics reported a significant increase in revenue and achieved profitability, but the stock price fell sharply due to investor disappointment [1][4][7] Revenue Performance - The company's revenue for the first quarter was nearly $121 million, almost double the $63.5 million from the same period in 2024, driven primarily by Briumvi sales [2][6] - Analysts had a collective revenue estimate of $117 million, indicating that the actual revenue exceeded expectations [4] Profitability - TG Therapeutics posted a net profit of just over $5 million, or $0.03 per share, compared to an almost $11 million loss in the first quarter of 2024 [4] - The consensus estimate for earnings per share was $0.16, suggesting that the actual profit fell short of analyst expectations [4][7] Pipeline Developments - The company is conducting two phase 1 trials for Briumvi: one for subcutaneous use in relapsing MS patients and another for myasthenia gravis [5] - Additionally, TG is developing a CAR T cell therapy, azercabtagene zapreleucel, which is currently in enrollment for a phase 1 trial [5] Guidance Update - TG Therapeutics raised its guidance for domestic Briumvi sales in 2025 to $560 million, up from a previous estimate of $525 million [6] - Overall revenue guidance was also increased to $575 million from $540 million [6]

Company Overview - TG Therapeutics, Inc. is a commercial stage pharmaceutical company based in Morrisville, North Carolina, known for marketing and selling Briumvi (ublituximab), which was approved in the US in 2022 for treating relapsing forms of multiple sclerosis (rMS) [2]. Market Position and Offerings - The company provides a platform for both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2]. Analyst Insights - Edmund Ingham, a biotech consultant with over 5 years of experience in the sector, has compiled detailed reports on more than 1,000 companies and leads the investing group Haggerston BioHealth [2].

Financial Data and Key Metrics Changes - U.S. net sales for BRIONVI reached approximately $119.7 million in Q1 2025, reflecting a 137% year-over-year growth and a 16% sequential increase from Q4 2024 [16][24] - GAAP net income for the quarter was approximately $5 million, or $0.03 per diluted share [25] - The company closed the quarter with $276 million in cash, cash equivalents, and investment securities, indicating a strong financial position [26] Business Line Data and Key Metrics Changes - BRIONVI's U.S. net sales exceeded internal expectations, marking the highest months of total new patient enrollment since launch, with March being the highest month for repeat prescribers [16][18] - The company reported that repeat prescriptions have now surpassed new prescriptions for the first time, indicating strong persistence trends [18] Market Data and Key Metrics Changes - The company is gaining approximately 25% of the IV segment market share, with no observed impact from competitive products like OCREVUS [30][31] - The hospital setting contributed approximately 60% of enrollments in March, highlighting a deepening footprint among institutional accounts [18] Company Strategy and Development Direction - The company aims to make BRIONVI the number one prescribed anti-CD20 therapy, focusing on a multi-phase launch strategy and enhancing the patient experience [9][13] - Plans include launching a direct-to-patient television commercial campaign and preparing for lifecycle innovations, including a subcutaneous formulation of BRIONVI [20][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued growth and potential for BRIONVI, citing strong demand, increasing prescriber confidence, and broad commercial execution [21][22] - The company is actively monitoring potential tariffs but does not anticipate a material impact on gross margins or overall financial performance [26] Other Important Information - The company is advancing its pipeline with a focus on the ENHANCE clinical trial and exploring new indications for subcutaneous BREONVY [10][12] - The company is also excited about its allogeneic CD19 CAR T cell therapy, azurecel, targeting progressive forms of MS [13] Q&A Session Summary Question: Competitive dynamics regarding OCREVUS and new patient share - Management noted that they are seeing strong market share gains and have not observed any impact from OCREVUS [30][31] Question: Update on gross to net trends and gross margin expectations - There was no material change in gross to net for the quarter, and the margins reported are expected to be consistent going forward [37][38] Question: Subcutaneous BREONVY pivotal trial details - The pivotal trial is expected to include two dosing regimens, with data likely to be available later this year [42][44] Question: Feedback on the thirty-minute infusion data - Positive feedback was received from physicians regarding the thirty-minute infusion, which is seen as a convenience for busy infusion centers [50] Question: Update on North Carolina plant for commercial scale manufacturing - The North Carolina facility will take several years to be operational for commercial manufacturing [58] Question: Product adherence metrics - Persistence trends remain strong and above expectations, although specific adherence metrics were not disclosed [64] Question: Percentage of BRIONVI patients switching from OCREVUS - The company has not seen material changes in the percentage of switches from OCREVUS, maintaining a healthy amount of switches since launch [71]

TG Therapeutics (TGTX) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.08 per share when it actually produced earnings of $0.15, delivering a surprise of 87.50%.Over the last four quarter ...